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Abstract
Lens epithelium derived growth factor (LEDGF), also known as PC4 and SFRS1 interacting protein 1 (PSIP1) and
transcriptional co-activator p75, is the cellular binding partner of lentiviral integrase (IN) proteins. LEDGF accounts for the
characteristic propensity of Lentivirus to integrate within active transcription units and is required for efficient viral
replication. We now present a crystal structure containing the N-terminal and catalytic core domains (NTD and CCD) of HIV-
2 IN in complex with the IN binding domain (IBD) of LEDGF. The structure extends the known IN–LEDGF interface,
elucidating primarily charge–charge interactions between the NTD of IN and the IBD. A constellation of acidic residues on
the NTD is characteristic of lentiviral INs, and mutations of the positively charged residues on the IBD severely affect
interaction with all lentiviral INs tested. We show that the novel NTD–IBD contacts are critical for stimulation of concerted
lentiviral DNA integration by LEDGF in vitro and for its function during the early steps of HIV-1 replication. Furthermore, the
new structural details enabled us to engineer a mutant of HIV-1 IN that primarily functions only when presented with a
complementary LEDGF mutant. These findings provide structural basis for the high affinity lentiviral IN–LEDGF interaction
and pave the way for development of LEDGF-based targeting technologies for gene therapy.
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Introduction
Integration of reverse transcribed viral cDNA into the host cell
genome is an essential step in the retroviral life cycle. This process
is catalyzed by integrase (IN), a virus-derived enzyme, which
carries out two separate reactions acting on both cDNA termini
(reviewed in [1,2]). Firstly, 39-processing takes place in the
cytoplasm of the host cell, in which a di- or trinucleotide is
hydrolytically removed from each cDNA end, exposing 39-
hydroxyl groups of invariant CA dinucleotides. The enzyme
remains attached to both viral cDNA ends within a higher order
pre-integration complex (PIC). The PIC is transported into the
nucleus and, upon locating a suitable chromatin environment, the
second reaction, strand transfer, ensues. During this step, the pair
of hydroxyl groups produced during 39-processing nick and join to
opposing strands of the cellular DNA, four to six base pairs apart,
depending on the retroviral genus. To complete the process,
cellular enzymes repair the integration site, resulting in a stable
provirus flanked by short duplications of the target DNA sequence.
Retroviral INs share a conserved three domain organization,
each containing a central catalytic core domain (CCD), flanked by
N- and C-terminal domains (NTD and CTD) [3–5]. The CCD
spans the most conserved region of IN and bears close structural
homology to prokaryotic transposases [6]. The enzyme active site
is comprised of three invariant acidic residues (the D,DX35E motif)
that coordinate a pair of Mg2+ cations during catalysis [7,8]. The
NTD forms a three-helical bundle, which folds around a zinc atom
coordinated by His and Cys residues of an HHCC motif [9,10].
The CTD features an SH3-like fold, is rich in basic residues and is
likely involved in DNA binding [11,12]. Despite Herculean efforts
directed towards characterization of this key antiviral drug target,
the structure of a full-length retroviral IN remains elusive. The
active form of retroviral IN is a tetramer [13–15], and a plausible
tetramer model for the apoenzyme was proposed based on a
crystal structure of a two-domain fragment of HIV-1 IN
containing its NTD and CCD (INNTD+CCD) [16].
Lentiviral DNA integration critically depends on lens epitheli-
um-derived growth factor (LEDGF) (reviewed in [17]). LEDGF
tightly associates with chromatin and has been implicated in
regulation of cellular gene expression, epigenetic chromatin
modifications and apoptosis [18–20]. The host factor directly
binds HIV-1, HIV-2, as well as other lentiviral INs and
dramatically stimulates their strand transfer activity [21–24].
LEDGF tethers lentiviral IN to host chromatin in the nucleus [24–
27] and plays a critical role in directing PICs to active genes
during integration [28–32]. LEDGF contains a pair of small
structural domains: an ,92 residue PWWP domain at its N-
terminus, responsible for binding to an as yet unidentified
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component of chromatin, and the IN binding domain (IBD,
residues 347–429) within its C-terminal portion [33–35]. The
CCD and NTD of IN were both implicated in LEDGF binding:
while the CCD is minimally sufficient, the NTD is required for
high affinity binding [27,36]. Deletion of the HIV-1 IN NTD, or a
mutation destabilizing zinc coordination within this domain (His-
12 to Asn), greatly reduced the interaction with LEDGF [27]. A
close homolog of LEDGF, hepatoma derived growth factor-
related protein 2 (HRP2), contains conserved PWWP and IBD-like
domains. Although HRP2 is able to interact with HIV-1 IN and
stimulate its enzymatic activity in vitro [33], it remains to be
established whether it plays a role in lentiviral integration.
The structure of the LEDGF IBD, composed of a pair of a-
helical hairpins, has been determined both separately and in
complex with the HIV-1 IN CCD [34,36]. In the INCCD:LEDG-
FIBD complex, Ile-365 of LEDGF inserts into a hydrophobic
pocket at the IN dimer interface. The interaction is further
bolstered by additional hydrophobic interactions between IN
residue Trp-131 and LEDGF Phe-406 and Val-408. Asp-366 of
LEDGF plays an important role in protein-protein recognition,
forming a pair of essential hydrogen bonds with the main chain
amides of IN residues Glu-170 and His-171 [36]. Mutation of
LEDGF Asp-366 to Asn ablated the interaction with all lentiviral
INs tested so far, indicating a common mechanism of recognition
[22]. In this work we extend the known lentiviral IN-LEDGF
interface to include contacts between the IN NTD and the IBD of
LEDGF. This part of the protein-protein interface is essential for
high affinity binding and stimulation of concerted DNA
integration, and allows designs of complementary pairs of IN
and LEDGF mutants for practical uses in gene therapy.
Results
Crystallization and Structure Determination
To further characterize the interface between lentiviral INs and
LEDGF, we obtained a complex of HIV-2 INNTD+CCD and
LEDGFIBD by co-expression, and crystallized it in two forms.
Although crystal form II diffracted to slightly lower resolution than
form I (Table 1), it resulted in a higher quality structure. Firstly,
form I displayed a higher degree of disorder and only three
quarters of the asymmetric unit (ASU) could be unambiguously
defined in electron density maps. Secondly, the twelve-fold non-
crystallographic symmetry (NCS) in form II dramatically increased
the observations:parameters ratio, resulting in a pseudo-high
resolution structure. The structures observed in both crystal forms
were overall equivalent, and the remainder of the paper will focus
on form II. Snapshots of electron density for the CCD-IBD
interface and Zn-His2Cys2 cluster of the NTD are shown in Figure
S1A and S1B. Of note, all previous HIV-1 IN CCD crystal
structures required Phe-185 to be mutated to Lys or His to
improve protein solubility. Such a mutation was not necessary to
crystallize the HIV-2 INNTD+CCD:LEDGFIBD complex. There-
fore, our structure is the first to include an HIV IN CCD with a
Phe residue naturally occurring at this position (Figure S1C).
Based on elution from calibrated gel filtration columns and
velocity analytical ultracentrifugation experiments, the purified
HIV-2 INNTD+CCD:LEDGFIBD complex behaved as a monodisperse
species with a calculated molecular mass of ,60 kDa (data not
shown). This size is consistent with a dimer of HIV-2 INNTD+CCD
plus one or two LEDGFIBD molecules, closely matching the basic
building unit observed in the crystal (Figure 1A, referred to as the
IN2LEDGF substructure). The substructure assembles further into
closed trimers with a three-fold NCS (Figure 1B), and four such
trimers accrue in the ASU to form a spherical structure containing
24 IN and 12 LEDGF chains (Figure 1C). The trimer is held
primarily via IN-IN (CCD-CCD, NTD-CCD and NTD-NTD)
interactions (Figure 1B), and the total buried surface area between
neighboring IN dimers is ,2,000 A˚2.
The IN–LEDGF Interface and the Role of the IN NTD
A total of,1,450 A˚2 of molecular surface is buried at the IN-LEDGF
interface within the IN2LEDGF substructure. HIV-1 and HIV-2 INs
share,60% amino acid sequence identity over the span of their CCDs.
Accordingly, the contacts between the HIV-2 IN CCD and the IBD are
very similar to those observed in the HIV-1 INCCD:LEDGFIBD
structure, and have been extensively discussed elsewhere [36].
Significant changes to this part of the interface occur due to amino
acid replacement at positions 128 and 129: HIV-2 encodes Met and
Val, respectively, while HIV-1 carries Ala in both cases. The HIV-2
residues are nevertheless involved in similar hydrophobic interactions:
the Met-128 side chain packs against Leu-368, Phe-406, and Val-408 of
LEDGF, while Val-129 contributes to the hydrophobic pocket that
buries LEDGF residue Ile-365 (Figure S2). As predicted [22,36], the
critical LEDGF Asp-366 residue forms a bidentate hydrogen bond to
the same backbone amides in HIV-2 and HIV-1 INs, even though the
side chains at these positions differ between viruses (Asn-170 and Thr-
171 in HIV-2; Glu-170 and His-171 in HIV-1).
In agreement with prior biochemical analyses [27], the NTD of
IN makes extensive contacts with LEDGF. A constellation of
acidic residues on the first helix (a1) of the NTD (Glu-6, Glu-10,
and Glu-13) faces positively charged residues on the a4 helix of the
IBD (Lys-401, Lys-402, Arg-404, and Arg-405). Side-chains of
LEDGF residues Lys-401, Arg-404, and Arg-405 are well ordered,
and a well-defined salt bridge involves IN residue Glu-10 and Arg-
405 of LEDGF (Figure 2A). The remaining side chains show
varying degrees of order and appear to contribute to the overall
charges of the interacting faces. The closely positioned and highly
conserved IN residue Glu-11 is not involved in the interface and
instead interacts with Lys-25 and Lys-186 of the same IN chain,
supporting NTD structural integrity and hence overall stability of
the IN2LEDGF substructure.
Author Summary
Retroviruses crucially rely on insertion of their genomes
into a host cell chromosome, and this process is carried
out by the viral enzyme integrase. HIV and other
lentiviruses also depend on LEDGF, a cellular chromatin-
associated protein, which binds their integrase proteins
and tethers them to a human chromosome. The interac-
tion between integrase and LEDGF can potentially be
exploited for directing integration of lentiviral vectors in
gene therapy applications, as well as for development of
antiretroviral drugs. Herein, we present a three-dimen-
sional structure of a protein–protein complex containing a
fragment of HIV integrase and the integrase-binding
domain of LEDGF. Our structure elucidates the hitherto
unknown LEDGF–integrase interface involving the amino
terminal portion of the viral enzyme. Using a range of
complementary approaches, we further show that these
novel protein–protein contacts are essential for the
function of LEDGF in HIV integration. The novel structural
details will be very useful for the development of HIV
inhibitors that target the integrase–LEDGF interaction.
Furthermore, they enabled us to design a mutant of HIV
integrase that depends on a reverse-engineered mutant of
LEDGF, providing an inroad to the design of LEDGF-based
lentiviral vector targeting strategies.
Gain-of-Function HIV-1 IN Mutants
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Figure 1. The HIV-2 INNTD+CCD:LEDGFIBD Structure and Multimeric Assemblies Found in the Crystal. (A) The IN2LEDGF substructure,
containing a dimer of INNTD+CCD and a single molecule of LEDGFIBD, the basic building unit of both crystal forms. IN chains are colored pale green and
cyan, and LEDGF is pink. Zinc atoms are shown as gray spheres. Residues involved in IN–LEDGF interfaces and discussed in the text are shown as
sticks and indicated with arrowheads. (B) The closed trimer of IN2LEDGF substructures. Colors and labels as in (A). (C) Stereo view of the higher order
assembly involving four IN2LEDGF trimers representing the entire ASU of crystal form II. Colors as in (A).
doi:10.1371/journal.ppat.1000259.g001
Table 1. Data collection and refinement statistics.
Crystal Form I Crystal Form II
Data Collection Space group P321 P212121
Cell dimension a, b, c (A˚) 210.5, 210.5, 162.6 201.4, 202.5, 280.5
Resolution (A˚) 44-3.06 (3.22-3.06)* 50-3.2 (3.37-3.20)
Total reflections 480,127 1,480,594
Unique reflections 77,620 188,459
Rmerge (%) 8.3 (52.1) 16.1 (56.2)
I/s(I) 16.1 (3.0) 13.0 (3.9)
Completeness (%) 99.1 (99.6) 99.9 (100)
Redundancy 6.2 (6.0) 7.9 (8.0)
Refinement: Resolution (A˚) 35-3.06 35-3.2
Number of reflections used 73,711 178,727
Rwork/Rfree(%) 27.3/29.6 22.5/23.4
Number of atoms: Protein 15652 46692
Number of atoms: Ligand/ion 48 48
R.m.s. deviations from ideal bond length (A˚) 0.015 0.006
R.m.s. deviations from ideal bond angles (u) 1.900 0.948
Ramachandran (%) most favored 87.4 91.4
Ramachandran (%) Additionally allowed 10.7 8.4
Ramachandran (%) Generally allowed 1.5 0.2
Ramachandran (%) Disallowed 0.4 0
*Values in parentheses are for the highest resolution shell.
doi:10.1371/journal.ppat.1000259.t001
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Acidic residues at IN positions 6, 10, and 13 are highly
conserved among HIV isolates, and those at positions 10 and 13
tend to be acidic within Lentivirus, whose members retain at least
one of the two negative charges (Figure 2B). Feline immunode-
ficiency virus (FIV) and maedi-visna virus (MVV) INs that lack
negative charges at positions 10 and 13, respectively, contain
additional acidic residues (Glu-7 and/or Glu-9), which should
preserve the negative charge of the NTD face. Overall, lentiviral
INs maintain two or more acidic residues within a1 of their NTDs,
which can be predicted to contribute to the interaction with the
positive face of the IBD. Conversely, the complementary basic
residues are conserved among all known LEDGF and HRP2
orthologs, with some variation only at the position corresponding
to LEDGF Arg-405, where Arg or Lys is accommodated
[22,24,33,34]. Of note, although some INs from nonlentiviral
genera contain acidic residues at positions corresponding to
residues 10 or 13 of lentiviral INs, these residues are not conserved
within or among these genera (data not shown).
The pair of NTDs belonging to the IN dimer of the IN2LEDGF
substructure exist in equivalent orientations with respect to the CCD
dimer and are supported by contacts with the CCDs involving three
salt bridges (Glu-11:Lys-186, Lys-20:Asp-193, and Glu-21:Arg-188)
as well as hydrophobic stacking interactions involving Lys-14 and
Tyr-15 of the NTD and Trp-131, Trp-132, and Lys-186 of the
CCD. An almost identical NTD-CCD interface was observed in the
crystal structure of the uncomplexed HIV-1 INNTD+CCD tetramer
[16] (Figure S3B, discussed in more detail below). Notably, the
interface was formed between a CCD of one IN dimer (green in
Figure S3B) and an NTD from another (yellow in Figure S3B), and
so the two structures present an interesting case of domain swapping
(Figure S3). The other NTD of the IN2LEDGF substructure (cyan in
Figure S3A) is important in forming the closed trimers as it interacts
with a second IN2LEDGF module through its A chain NTD and the
IBD (Figure 1B).
The NTD–IBD Interface Is Critical for the High Affinity IN–
LEDGF Interaction and Affords Functional Charge
Reversal of Opposing Molecular Faces
The domain–domain interfaces observed in the crystal structure
were targeted by mutagenesis to investigate their functional
relevance. Three LEDGF mutants were designed to eliminate or
reverse the positive charges facing the IN NTD: K401A/K402A/
R405A (AAA), K401E/K402S/R405E (ESE), and K401E/
K402E/R405E (EEE). The K360E mutation targeted a salt bridge
from LEDGF residue Lys-360 to IN Asp-167 within the IBD-CCD
interface [36], and K392E was made to disrupt a potential
interaction between Lys-392 and Glu-6 within the secondary
NTD-IBD interface that contributes to substructure trimerization
(Figure 1B). The mutants were tested in a His6-tag pull-down assay
for binding to the INs from HIV-1, HIV-2, and three nonprimate
lentiviruses (bovine immunodeficiency virus [BIV], MVV, and
equine infectious anemia virus [EIAV]). Consistent with earlier
reports [22,27], wild type (WT) LEDGF was pulled down by all WT
lentiviral INs, but not with the HIV-1 H12N mutant (Figure 3A).
His-12 is involved in zinc coordination and is, therefore, critical for
structural integrity of the NTD [37]. Also in agreement with prior
work [22,34], D366N LEDGF did not interact with HIV-1 IN
(Figure 3A) or any of the remaining INs (data not shown). Mutations
reversing the positively charged face of the IBD disrupted binding to
HIV-1 and HIV-2 INs (Figure 3A, lanes 5, 6, 11, and 12), and only
very weak binding was detected for AAA LEDGF (lanes 4 and 10).
Furthermore, the EEE mutations ablated the interaction with
nonprimate lentiviral INs (lanes 14, 16, 18; data not shown). HIV-1
IN binding to LEDGF mutant K360E was also affected, albeit to a
lesser degree (lane 7), while K392E was pulled down most efficiently
of all LEDGF mutants tested (lane 8).
The yeast two-hybrid technique proved more sensitive than pull
down analyses when applied to weak interactions between IN and
LEDGF mutants [38]. Full-length HIV-1 IN fused to the DNA
binding domain of Gal4 serves as bait, and binding of the LEDGF
IBD fused to Gal4 transcription activation domain is reflected by
b-galactosidase reporter gene activity. In this assay, LEDGF
mutants K360E and K392E showed wild type levels of binding to
HIV-1 IN, AAA bound at about 5% of WT, while similarly to
D366N, the ESE and EEE mutants failed to interact at detectable
levels (Figure 3B), essentially corroborating the results of the His6-
tag pull down experiments. To demonstrate that these observa-
tions were not due to off-site effects such as defective folding or
reduced expression of the LEDGF mutants and to validate the
novel NTD-IBD interface further, the complementary IN residues
were mutated, producing a reversed charge D6K/E10K/E13K
(KKK) HIV-1 mutant. Impressively, KKK IN robustly interacted
Figure 2. Details of the NTD–IBD Interface. (A) The acidic IN residues and basic LEDGF residues are shown as sticks. The 2Fo-Fc electron density
map, contoured at 1s, is shown in pale blue. (B) Partial amino acid sequence alignment including residues 1–17 of human (HIV-1 and HIV-2) and non-
primate (BIV, EIAV, FIV, and MVV) lentiviral INs. Conserved residues are shown in bold; His-12 and His-16 of the invariant HHCC motif are highlighted
in yellow. Acidic residues known (for HIV-1 and HIV-2) or proposed to interact with the positively charged face of the IBD are orange.
doi:10.1371/journal.ppat.1000259.g002
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with the complementary EEE LEDGF mutant, generating ,40%
of WT-WT b-galatosidase activity and furthermore, it failed to
interact with WT LEDGF (Figure 3B). The double HIV-1 IN
E10K/E13K (KK) mutant bearing charge reversals at the two
more conserved acidic positions (Figure 2B) likewise gained the
ability to interact with EEE LEDGF while displaying no detectable
binding to the WT protein in this assay (Figure 3B).
The NTD–IBD Interface and LEDGF-Dependent HIV-1 IN
Strand Transfer Activity
Whereas in vivo retroviral INs must integrate both viral cDNA
ends in a concerted fashion, their recombinant forms are typically
more proficient at half-site integration (i.e. integration of a single
viral DNA end into one strand of a target DNA molecule). The
relative efficiencies of concerted and half-site integration processes
Figure 3. Functional Importance of the NTD–IBD Charge–Charge Interface for the Lentiviral IN–LEDGF Interaction. (A) Pull down
experiments. Non-tagged WT, D366N, AAA, ESE, EEE, K360E, or K392E LEDGF proteins were incubated with C-terminally His6-tagged forms of HIV-1 IN
mutant H12N, WT HIV-1 IN, HIV-2 IN, BIV IN, MVV IN, or EIAV IN (as indicated) in the presence of Ni-NTA agarose. Bound proteins were separated in
11% sodium dodecyl sulfate polyacrylamide gels and visualized with Coomassie Blue. Input quantities of LEDGF proteins are shown below the main
gel. (B) Yeast two-hybrid analyses. The IN–LEDGF interaction assay [22,38] is based on transactivation of the b-galactosidase gene in S. cerevisiae
indicator cells Y187. Relative b-galactosidase activities produced by yeast co-transformed with the indicated IN and LEDGFIBD mutants are shown on a
log scale, with 100% corresponding to the WT bait/WT prey condition. The background of the assay is defined by WT IN in the presence of empty
prey vector and is shown as a gray line. Each bar represents a mean value; standard deviations were calculated based on results of quadruplicate
measurements. Values exceeding the background are shown atop the bars.
doi:10.1371/journal.ppat.1000259.g003
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strongly depend on the in vitro reaction conditions, with parameters
such as the length of the donor DNA, enzyme source and
concentration, and presence of crowding agents greatly affecting
the outcomes [22,39–41]. The use of a short mimic of the viral
cDNA end (referred to as donor DNA substrate) and supercoiled
target DNA conveniently allows discrimination between products
of concerted and half-site integration (Figure 4A).
LEDGF robustly promotes the strand transfer activities of
divergent lentiviral INs in vitro, although the fidelity of LEDGF-
mediated strand transfer varies for the different INs [21,22].
Intriguingly, while simulating half-site strand transfer activity of
HIV-1 IN under all reported conditions, the host factor has the
capacity of to either inhibit [42] or bolster [43] its concerted
integration activity.
In the presence of 10 nM 500-bp donor substrate, 2.9 kb
supercoiled plasmid DNA (pGEM), and WT LEDGF, WT HIV-1
IN carries out robust, predominantly half-site strand transfer [22]
(Figure 4B, lane 3); half-site products migrate in agarose gels well
above the open circular form of the target, while concerted
integration products appear as linear (,4,000 bp) DNA species
(Figure 4A and 4B). In agreement with earlier observations, the
reaction was severely affected by the critical LEDGF D366N
mutation (Figure 4B, lane 4). Despite greatly reduced binding
affinity, the EEE LEDGF mutant retained the ability to stimulate
half-site strand transfer activity, evident from accumulation of both
donor-target and donor-donor products (lane 5). Concordantly,
both WT and EEE LEDGF proteins stimulated the half-site
activity of KK and KKK HIV-1 IN mutants. The KKK mutant,
while significantly less active than WT IN, was somewhat more
responsive to the mutant form of LEDGF (compare lanes 10 and
11). Based on these observations we conclude that the intact NTD-
IBD interface and hence the full affinity of the IN-LEDGF
interaction is not required for stimulation of half-site integration.
This finding was not entirely unexpected, as HRP2, which binds
HIV-1 IN with significantly lower affinity than LEDGF, is able to
stimulate half-site integration in vitro to a similar extent [33]. Of
note, because the ability of D366N LEDGF to bolster half-site
strand transfer is severely repressed [34] (Figure 4B, lane 4), we
argue that the stimulation of HIV-1 IN by LEDGF, and by EEE
LEDGF, in particular, is strictly dependent on the direct protein-
protein interaction. Concordantly, histidine and adenine auxotro-
phic AH109 yeast cells co-transformed with WT IN and EEE
LEDGF Gal4 chimeras displayed a very slow growth phenotype
on solid media lacking these nutrients, confirming a weak residual
interaction (data not shown). In contrast, evidence for an
interaction between D366N LEDGF and WT HIV-1 IN was
not observed, even under these conditions [22].
In agreement with earlier observations [22], EIAV IN was
highly competent for concerted integration in the presence of
LEDGF (Figure 4C, lane 3). Notably, the concerted strand transfer
activity of EIAV IN was severely reduced when EEE LEDGF was
used (lane 4). At the same time, the trace levels of half-site activity
were not significantly affected. These results indicated that the
NTD–IBD interface bears a special significance for concerted
lentiviral DNA integration. In the course of optimizing HIV-1 IN
strand transfer conditions, we discovered that increasing donor
DNA concentration greatly enhanced the yield of LEDGF-
dependent concerted integration products (refer to Text S1 and
Figure S4 for validation of the assay). This novel assay afforded a
convenient means for studying the affects of mutations on LEDGF
and HIV-1 IN function (Figure 4D). As expected, the D366N
LEDGF mutant, severely defective for IN binding, failed to
stimulate concerted integration (Figure 4D, compare lanes 4 and
5). Reaction products formed in the presence of AAA, ESE, and
EEE LEDGF mutants show that successive addition of net
negative charge at this location decreases the ability of the cofactor
to stimulate concerted integration, with hardly any product visible
with the EEE mutant (Figure 4D, lanes 6–8). However, in
agreement with the data discussed above (Figure 4B), these
mutants retained the ability to stimulate half-site integration. As
expected, LEDGF mutants K360E and K392E displayed WT
activity (Figure 4D, lanes 9 and 10).
Significantly, both KK and KKK IN mutants gained concerted
integration activity in the presence of EEE LEDGF. Furthermore,
both IN mutants, and most dramatically KKK IN, favored the
mutant LEDGF form (Figure 4D, lanes 13–16). These results
confirm that the mutant proteins are properly folded and that the
effects observed are due to the modification of the protein-protein
interface. They also suggest a possibility to engineer a gain of
function HIV-1 IN mutant, active specifically in the presence of a
complementary mutant of the host factor.
The NTD–IBD Interface Is Important for LEDGF Cofactor
Function During HIV-1 Infection
To test the importance of the IBD-NTD interface in the context
of viral replication, we used an established mouse LEDGF
knockout model [29]. Although HIV-1 cannot complete its
replication cycle in murine cells due to post-integration blocks,
its reverse transcription and integration proceed normally and
depend on LEDGF [29]. Ledgf-null mouse embryo fibroblasts
(MEFs) transfected with a human LEDGF expression vector or its
mutant forms were infected with single-round, vesicular stomatitis
virus glycoprotein G (VSV-G)-pseudotyped HIV-1 vectors ex-
pressing a luciferase reporter gene (HIV-Luc), and the levels of
luciferase activity in cell extracts were measured 44 h post
infection. The WT and mutant LEDGF proteins were well-
expressed, and endogenous mouse LEDGF protein, as predicted,
was not detected in cells transfected with the empty vector
(Figure 5A). WT LEDGF expression increased the level of
knockout cell infection five to ten-fold as compared to cells
carrying the empty vector. As expected [29], the D366N LEDGF
mutant failed to stimulate the basal level of HIV-Luc infection.
LEDGF AAA, K360E, and K392E by contrast supported similar
levels of HIV-Luc infectivity as WT LEDGF, while its K401E/
K402A/R405E (EAE, similar to ESE) and EEE mutants
functioned at ,25% and 10%, respectively (Figure 5A). An
additional LEDGF mutant combining the EEE and K360E
mutations, and therefore lacking the Lys-360:Glu-167 IBD–CCD
salt bridge (E4, Figure 1B), supported the lowest level of infectivity
(Figure 5A). These results tie in well with the in vitro interaction and
activity data, extending the biological significance of the NTD-
IBD interface.
Release and infectivity of HIV-1 mutants carrying substitutions
at IN positions 6, 10, and 13 were impaired to various extents. The
KKK variant was most affected, failing to support any appreciable
infectivity under a variety of conditions. This result was not
unexpected, as often subtler changes in IN grossly affect various
HIV-1 replication steps [44]. The nature of the defects observed
with mutant viruses will be elaborated elsewhere. As demonstrated
above, the double mutant carrying substitutions at the more
conserved NTD acidic positions (E10K/E13K) was able to
functionally interact with EEE LEDGF. Although KK HIV-Luc
supernatants harvested from transfected 293T cells contained
approximately 30% of reverse transcriptase (RT) activity com-
pared to WT, suggesting subtle release or maturation defects, in
agreement with the in vitro data, this virus was infectious when
presented with LEDGF EAE or EEE (Figure 5B). Significantly,
KK HIV–Luc infectivity was negligible in the presence of WT
Gain-of-Function HIV-1 IN Mutants
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LEDGF, generating luciferase levels comparable to the empty
vector control (Figure 5B). In repeat experiments, the infectivity of
the KK virus in the presence of LEDGF EEE varied between 3.5
and 40.8% (19.3612.3% for n= 6 experiments) of WT HIV-Luc
infectivity in the presence of WT LEDGF. These results confirm
that modifications of the charge-charge NTD-IBD interface allow
creation of viable gain of function IN mutants able to functionally
interact with an engineered version of LEDGF.
Discussion
In this work we extended the known lentiviral IN-LEDGF
interface to include the interactions between the NTD of IN and
the IBD of LEDGF. Since there is no evidence that the CTD of IN
or LEDGF regions outside of the IBD are involved in the
interaction, the contacts observed in our crystal structure may very
well represent the entire IN-host factor interface. These novel
Figure 4. Effects of Mutations within the NTD–IBD Interface on LEDGF–Dependent Strand Transfer Activities of Lentiviral INs. (A)
Schematic of the reactions mediated by IN in the presence of circular DNA target: concerted integration results in a linear product while half-site
reactions produce branched molecules (circular half-site and donor-donor). (B) HIV-1 IN activity under established conditions that favor half-site
integration [22]. WT, KK, or KKK HIV-1 IN was incubated with 10 nM 500-bp donor DNA and supercoiled target DNA in the absence (lane 2) or
presence (lanes 3–11) of WT, D366N, or EEE LEDGF. The products separated in an agarose gel were detected with ethidium bromide. Lane 1
contained a mock sample, with both IN and LEDGF omitted. (C) EIAV IN reactions. EIAV IN was incubated with 10 nM 225-bp donor DNA and
supercoiled target DNA in the absence (lane 2) or presence (lanes 3 and 4) of WT or EEE LEDGF, as indicated. Lane 1 contained a mock sample without
IN and LEDGF; lane 5 contained IN and WT LEDGF without donor DNA; lane 6 contained 10 ng of singly-nicked pGEM-9Zf(-) [22] as a migration
standard for the open circular (o.c.) form of target DNA. (D) Enhanced concerted HIV-1 integration assay using an elevated input of donor DNA (for
details, see Text S1 and Figure S4). WT, KK, or KKK HIV-1 IN was incubated with 0.5 mM pre-processed 32-bp donor and supercoiled target DNA in the
presence of WT, D366N, AAA, ESE, EEE, K360E, or K392E LEDGF. Migration positions of various DNA species (size standards, supercoiled [s.c.] and o.c.
target, donor, and reaction products) are indicated.
doi:10.1371/journal.ppat.1000259.g004
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structural details will invariably aid the development of inhibitors
of the IN-LEDGF interaction. Intriguingly, both crystal forms of
the HIV-2 INNTD+CCD:LEDGFIBD complex contained closed
trimers of the IN2LEDGF substructure held together primarily by
IN-IN contacts. Based on the three-fold symmetry of this
assembly, we tentatively speculate that it could reflect packing
arrangement of IN molecules within retroviral capsids, which too
feature three-fold symmetry [45]. In both crystals the closed
trimers further associated into a spherical particle containing
twenty four IN chains, with their C-termini projecting inwards and
the N-termini outwards. It remains to be determined if the higher
order multimers of the IN2LEDGF substructure are biologically
relevant. Such evidence could come, for example, by observing
similar multimers in crystals of a divergent retroviral IN. Although
we have not detected analogous large-sized complexes in solution,
the calculated concentration of IN within retroviral capsids is very
high [46], presenting an environment where it may very well
adopt a paracrystalline state.
Mounting experimental evidence suggests that the active form of
retroviral IN is a tetramer [13–15]. Based on a crystal structure of
the HIV-1 INNTD+CCD fragment, Craigie and colleagues proposed
a plausible model for the synaptic IN tetramer (dimer of dimers)
[16]. Notably, the positions of the IN NTDs relative to the CCD
dimer and the supporting NTD-CCD contacts observed in our
HIV-2 INNTD+CCD:LEDGFIBD complex were seen in the earlier
structure, where the NTDs mediated contacts between IN dimers
[16]. One significant difference is that in the tetramer model, the
NTD occupying the position primed for the interaction with the
IBD is donated by the other IN dimer [16] (Figure S3A and S3B).
Such domain swapping is quite common, representing one of the
mechanisms for homomeric protein-protein interactions [47].
However, it is important to note an ambiguity of the NTD
assignments in the HIV-1 INNTD+CCD structure, which lacked
appreciable electron density for the NTD-CCD linkers [16].
Nevertheless, the NTD-CCD interface observed in the two
independent structures is almost certainly biologically relevant. If
IN dimers do indeed swap their NTDs during tetramerization, the
LEDGF binding platform would include a CCD dimer and an
NTD from a separate IN dimer (Figure S3C). Alternatively,
LEDGF binding to an IN dimer would lock one NTD in the
orientation primed for tetramerization (Figure S3D). In either case,
upon binding, the co-factor would enhance the thermodynamic
stability of the tetramer. It is a tetramer of IN that mediates synapsis
of a pair of donor DNA molecules [15] and, concordantly, the
NTD-IBD contacts uncovered here are specifically required for
concerted DNA integration. The model can also explain the
surprising ability of LEDGF to inhibit HIV-1 concerted integration
under some in vitro conditions [42]. LEDGF binding to a dimer of
IN would fixate either one or both NTDs, preventing them from
functionally interacting with a second IN dimer (Figure S3). Thus,
the concentration of IN, LEDGF and donor DNA substrate in the
reaction mixture, as well as the order of component addition
significantly influence the outcome of the reaction (Ref. [43] and
data not shown). Of note, one recent study suggested that IN must
exist in a lower multimeric state, likely a dimer, before interacting
with the donor DNA for proper synaptic complex formation [48].
The enhanced concerted integration assay described herein will be
very useful in future biochemical and structural studies of HIV-1
IN. Furthermore, other lentiviral INs, and in particular EIAV IN,
carry out very efficient LEDGF-dependent concerted integration
utilizing oligonucleotide donor DNA substrates under similar
reaction conditions (data not shown).
Figure 5. LEDGF Residues Lys-401, Arg-404, and Arg-405 Play a Crucial Role in HIV-1 Infection. (A) Relative infectivity of VSV G-
pseudotyped WT HIV-Luc virus on Ledgf-null E2 MEFs transfected with human WT, AAA, EAE, EEE, E4, or D366N LEDGF expression vectors, as
indicated. Infectivity of the virus in the presence of WT LEDGF was set to 100%; mean values and standard deviations combine data of two
independent sets of transfections (each with infections performed in duplicate). (B) Infectivity of HIV-Luc bearing KK mutations in IN on E2 MEFs
transfected with WT, EAE, or EEE LEDGF. Infectivity is expressed as a percentage of WT virus on the cells transfected with WT LEDGF. Western blots
above the graphs show expression levels of LEDGF proteins and actin loading control.
doi:10.1371/journal.ppat.1000259.g005
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Using complementary approaches we demonstrated that the
NTD-IBD interface is important for the functional Lentivirus-host
interaction. Compared to the lock-and-key CCD-IBD interface,
the contacts involving the NTD are based on charge-charge
interactions and therefore lend themselves to complementary
reverse-charge engineering. Since LEDGF has been shown to
target lentiviral integration to active transcription units [28–30], it
has been speculated that modified versions of the host factor could
be used to control integration site selection. Safety of retroviral
vectors would be greatly improved if they could be directed
towards specific pre-determined loci and away from proto-
oncogenes [49]. In one recent work, a fusion of the DNA binding
domain of bacteriophage l repressor and the IBD of LEDGF
targeted HIV-1 integration nearby l operator sequences in vitro
[50]. One fundamental problem can thwart practical application
of such approaches. When delivered into the cell, the targeting
factor, associated with a limited number of chromosomal loci, will
have to compete with a vast excess of endogenous LEDGF for the
incoming preintegration complex. Knockout or knockdown of
endogenous LEDGF would unlikely be a practical or safe solution,
especially considering its emerging role in epigenetics [18]. Here
we demonstrated that an HIV-1 IN mutant carrying two reverse
charge mutations within the NTD gained the ability to
functionally interact with a modified version of LEDGF, while
remaining basically unresponsive to the WT protein. Although the
efficiency of the current system is somewhat modest, our results
present a proof of principle that it is possible to engineer a viable
complementary pair of IN and LEDGF mutants that could allow
future development and practical applications of LEDGF-based
lentiviral vector technologies.
Materials and Methods
Recombinant DNA
Compatible plasmids pCDF-HIV2-INNTD+CCD and pES-IBD-
3C7 were used for co-expression of HIV-2 INNTD+CCD and
LEDGFIBD in bacteria. To obtain the former, a fragment
encoding residues 1–209 of HIV-2 IN was inserted between NcoI
and BamHI sites of pCDF-Duet1 (Novagen); the latter was made
by TA-cloning of a PCR fragment encoding LEDGF residues
347–471 with an internal human rhinovirus 14 (HRV14) 3 C
protease cleavage site (LEVLFQGP, C-terminal to Val-435) into
pET-SUMO (Invitrogen). pCPH6P-HIV1-IN, used for expression
of full-length HIV-1 IN, was obtained by replacement of an XmaI/
XhoI fragment encoding BIV IN in pCPH6P-BIV-IN [22] with a
fragment coding for HIV-1HXB2 IN. Mutations were introduced
into pCPH6P-HIV1-IN and pFT1-LEDGF [51] using the
QuikChange procedure (Stratagene). For yeast two-hybrid assays,
mutations were introduced into pCPY414-DBD-IN and
pCPY426-AD-IBD [38] by swapping wild type IN and LEDGF
fragments with their mutant forms. For virus infectivity assays,
mutations were introduced into the env-deficient HIV-1 proviral
clone pNLX.Luc(R-) encoding HIV-1 with a gene for firefly
luciferase in place of Nef (HIV-Luc) and pIRES2-eGFP-LEDGF,
as previously described [29,52]. For production of SUMO
protease, a PCR fragment encoding the catalytic core domain of
Saccharomyces cerevisiae Ulp1 (residues 403–621) [53] was subcloned
into pCPH6P-BIV-IN, replacing the BIV IN coding sequence to
give pCPH6P-Ulp1CD. All DNA constructs made in this work
were verified by sequencing to avoid inadvertent mutations.
Protein Expression and Purification
To obtain HIV-2 INNTD+CCD:LEDGFIBD complex for crystal-
lography, Escherichia coli PC2 cells [22] co-transformed with pCDF-
HIV2-INNTD+CCD and pES-IBD-3C and grown in LB medium in
the presence of 50 mg/ml kanamycin and 100 mg/ml spectino-
mycin to an A600 of ,1.0 were supplemented with 50 mM ZnCl2
and induced with 0.3 mM isopropyl-b-D-thiogalactopyranoside.
Following 4 h induction at 22uC, cells were harvested and stored
at 280uC. For purification, cells were lysed by sonication in 1 M
NaCl, 20 mM imidazole, 0.2 mM PMSF, 50 mM Tris-HCl,
pH 7.4, and the protein complex was captured on Ni-NTA
agarose (Qiagen). Following extensive washing the protein was
eluted in 1 M NaCl, 200 mM imidazole, 50 mM Tris-HCl,
pH 7.4. The His6-SUMO tag was cleaved by overnight incubation
with SUMO protease at 7uC in the presence of 2 mM DTT. The
sample was diluted with four volumes of 1 M NaCl, and the
released His6-SUMO was depleted by absorption onto a 5-ml
HisTrap column (GE Healthcare). Residues C-terminal to the
IBD were removed by overnight digestion with HRV14 3 C
protease in the presence of 10 mM DTT at 7uC. The complex was
then purified by chromatography over a Superdex-200 column
(GE Healthcare) in 1 M NaCl, 50 mM Tris-HCl, pH 7.4,
concentrated to 17 mg/ml, supplemented with 10 mM DTT
and 10% glycerol, and flash-frozen in liquid nitrogen.
Non-tagged wild type and mutant HIV-1 IN proteins used in
strand transfer assays were produced in PC2 cells transformed
with pCPH6P-HIV1-IN or its mutant forms as previously
described [22]. The His6-tag was removed by digestion with
HRV14 3 C protease. Non-tagged EIAV IN and C-terminally
His6-tagged HIV-1, HIV-2, BIV, EIAV, and MVV IN proteins
have been reported [22]. Wild type and mutant LEDGF proteins
were made according to [51]. The SUMO protease Ulp1 catalytic
domain fragment was produced in PC2 cells transformed with
pCPH6P-Ulp1CD and purified as described in [53].
Crystallization and Structure Determination
Vapor diffusion crystallization experiments were set up at 18uC
in hanging drops by mixing 1 ml HIV-2 INNTD+CCD:LEDGFIBD
complex at a concentration of 4 mg/ml in 20 mM Tris-HCl,
pH 7.4, 300 mM NaCl, and 2 mM dithiothreitol (DTT) with 1 ml
reservoir solution containing either 2.6 M sodium acetate, 0.1 M
KI and 0.1 M Bis-Tris propane-HCl, pH 7.0 (form I) or 2.5 M
sodium acetate, 10 mM MgCl2, and 0.1 M Bis-Tris propane-HCl,
pH 7.0 (form II). Crystals of form I appeared within 24 h and
reached the maximum size of ,30063006300 mm within 10–30
days, while those of form II appeared within a week and grew over
several months to ,15061506150 mm. Both types of crystals
were cryoprotected in 25% glycerol, 2.6 M sodium acetate,
10 mM MgCl2, 0.1 M Bis-Tris propane-HCl, pH 7.0. Diffraction
data were collected to a resolution of 3.0 A˚ (form I) and 3.2 A˚
(form II) at the European Synchrotron Radiation Facility (ESRF)
beamline ID23-1 at 100 K. The data were processed using
MOSFLM [54] and SCALA [55] part of the CCP4 project [56].
Crystal form I belonged to the space group P321 with unit cell
parameters a = b = 210.5 A˚, c = 162.6 A˚, a=b= 90u, and
c= 120u. The structure was solved by molecular replacement
with MOLREP [57] using three individual search models in the
following order. First, three dimers of CCDs (chains A and B from
2b4j) were located, forming a trimer of dimers, followed by a single
IBD molecule (chain C from 2b4j) per CCD dimer, and finally the
NTDs (chain A residues 1–45 from 1k6y) [16,36]. After rigid body
refinement, it became clear that a fourth IN dimer with
corresponding IBD molecule was located out of the plane of the
original trimer of dimers, and that this new dimer formed a similar
trimer of dimers via the crystallographic three-fold axis. The ASU
contained twelve protein chains and over 70% solvent. The
structure was refined using REFMAC [58] and PHENIX [59],
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including translation, libration and screw (TLS) refinement, with
manual model building in COOT [60].
Form II crystals belonged to the space group P212121 with unit
cell parameters a = 201.4 A˚, b = 202.5 A˚, c = 280.5 A˚, and
a= b= c= 90u. A high degree of NCS was expected due to the
large unit cell. Therefore, to reduce potential bias in Rfree
estimation, the test reflection set was chosen in thin shells using
SFTOOLS, part of the CCP4 program suite [56]. The structure was
solved by molecular replacement in PHASER [61], using a search
model containing the dimeric IN assembly plus an associated
LEDGF chain as observed in form I. The structure was refined
using simulated annealing in PHENIX and restrained refinement
in REFMAC, imposing tight 12-fold NCS restraints. Positive Fo-Fc
density was observed at the known binding sites for zinc and
magnesium and the corresponding atom was added to the
structure. Details on data collection and refinement statistics are
shown in Table 1. Diffraction data and the resulting structure
derived from crystal form II were deposited to the protein
databank (PDB ID 3f9k), and those for form I are available upon
request.
Protein–Protein Interaction and Strand Transfer Activity
Assays
His6-tag pull-down and yeast two-hybrid assays were performed
as described previously [22,34,38]. The indicator S. cerevisiae strains
Y187 and AH109 were from BD Biosciences. Untagged,
recombinant INs were used in all strand transfer assays. HIV-1
and EIAV integration assays with the respective 500-bp and 225-
bp RU5 donor DNA substrates were carried out as previously
described [22]. HIV-1 donor DNA was obtained as a PCR
product using Pfu DNA polymerase (Stratagene) with the primer
pair 59-GGACTGAGGGGCCTGAAATGAGC/59-ACTGT-
TGGGTGTTCTTCACCGCCCC GCGAGCT and pU3U5
template; primers 59-TTAAGTTGGGTAACGCCAGG/59-
ACT GTAGGATCTCGAACAGAC and pU3U5-EIAV tem-
plate were used to make the EIAV donor [22,46].
For enhanced HIV-1 concerted integration assays, donor DNA
was prepared by annealing DNA oligonucleotides 59-CCTT-
TTAGTCAGTGTGGAAAATCTCTAGCA or 59-CCTTTT-
AGTCAGTGTGGAAAATCTCTAGCAGT and 59-ACTGC-
TAGAGATTTT CCACACTGACTAAAAGG to create a
32 bp mimic of the pre-processed or non-processed HIV-1 U5
cDNA terminus, respectively. Two ml HIV-1 IN in 750 mM NaCl,
2 mM DTT, 20 mM Tris-HCl, pH 7.4 (DB) was added to 36 ml
master mix containing 0.55 mM donor DNA and 0.30 mg
supercoiled pGEM-9Zf(-) target DNA in 25.3 mM NaCl,
5.5 mM MgSO4, 11 mM DTT, 4.4 mM ZnCl2, 22 mM
HEPES-NaOH, pH 7.4. Following a 3–5 min pre-incubation at
room temperature, reactions were supplemented with 2 ml
LEDGF in DB and allowed to proceed at 37uC for 30 min. The
final concentrations of HIV-1 IN and LEDGF were both 0.6 mM.
The reactions were stopped by addition of 25 mM EDTA and
0.5% SDS. The products deproteinized by digestion with 30 mg
Proteinase K for 1 h at 37uC and ethanol precipitation were
resolved by electrophoresis in 1.5% agarose gels and detected
using ethidium bromide.
For sequencing analysis, reaction products migrating as a band
of ,3 kb were isolated from a 1.5% agarose gel and converted
into fully double stranded forms by treatment with W29 DNA
polymerase (New England Biolabs) in the presence of 500 mM
dNTPs. The DNA was then 59-phosphorylated and ligated to a
blunt-ended 1.2-kb PCR fragment spanning the Tn5 aminogly-
coside-39-O-phosphotransferase gene flanked by KpnI sites [22].
Competent DH5a E. coli cells were transformed with the ligation
mixture. Plasmids were isolated from individual kanamycin-
resistant colonies, and those releasing fragments of expected sizes
(,3 and 1.2 kb) upon digestion with KpnI, were sequenced using
primers annealing within the Tn5-derived fragment.
Infectivity Assays
Single cycle infectivity assays were done as described elsewhere
[29,62]. Briefly, VSV-G-pseudotyped HIV-Luc carrying various
IN alleles generated by transfecting 293T cells were titered using a
32P-based reverse transcriptase (RT) assay. The Ledgf-null E2(2/
2) mouse embryo fibroblasts (MEFs) transformed with simian
virus 40 large T antigen were previously described [29]. Cells
transfected with empty, WT, or mutant LEDGF pIRES2-eGFP
expression vectors and sorted by FACS to enrich the GFP-positive
population were lysed for western blot analyses or plated for
infections. 10 h after plating, the cells were infected with equal
RT-cpm of HIV-Luc variants. Cells were lysed and luciferase
activity relative to the total protein content of the lysates was
measured 44 h post infection.
Supporting Information
Text S1 Validation of LEDGF-Dependent Concerted HIV-1 IN
Strand Transfer Activity
Found at: doi:10.1371/journal.ppat.1000259.s001 (0.04 MB
DOC)
Figure S1 Examples of Electron Density for Different Regions of
the Structure. (A) The CCD-IBD interface with crucial LEDGF
residues Asp-366 and Ile-365 labeled. In all panels the 2fo-fc
electron density contoured at 1.5 s level is shown as chicken wire
in blue, and protein residues are represented as sticks. Coloring of
carbon atoms is related to their chain (green - IN chain A, cyan -
IN chain B, and pink - LEDGF chain C); nitrogen, oxygen, and
sulfur are blue, red, and yellow, respectively. (B) The HHCC
motif, including a coordinated Zn atom (gray sphere). (C) The
native side-chain and corresponding electron density of HIV-2 IN
residue Phe-185.
Found at: doi:10.1371/journal.ppat.1000259.s002 (6.93 MB TIF)
Figure S2 Stereo Image Showing Details of the HIV-2 IN
CCD-LEDGF IBD Interface. Interacting residues are shown as
sticks and are labeled. Cartoon and carbon atoms are colored
according to their chain (green - IN chain A, cyan - IN chain B,
and pink - LEDGF chain C). Hydrogen bonds between Asp-366
and the main chain amides of IN residues Asn-170 and Thr-171
are shown as black dashes.
Found at: doi:10.1371/journal.ppat.1000259.s003 (1.28 MB TIF)
Figure S3 A Model for IN Tetramerization via Inter-Dimer
NTD Swapping. (A) The IN2LEDGF substructure is shown in
green, cyan, and pink (as in Figure 1A). The NTD colored dark
blue belongs to a separate IN2LEDGF unit, its contacts with the
IBD stabilize the closed trimer (Figure 1B). (B) The structure of
uncomplexed HIV-1 INNTD+CCD (PDB ID 1k6y), crystallized as a
tetramer (dimer of dimers). One dimer of IN (green and cyan) is
shown with the CCDs in the same orientation as in panel A, with
the tetramer completed by the dimer colored yellow and orange.
The yellow NTD enclosed in an oval is in the same position and
orientation as the green NTD in (A), while the orange NTD
(circled) is in a similar position but a different orientation to the
dark blue NTD in (A). (C) Schematic diagram of the proposed
assembly and domain interactions within the active synaptic
complex (IN CTDs are not shown). Coloring of the IN and IBD
molecules is same as in (A) and (B); large circles represent the IN
CCDs, small circles the NTDs, and parallelograms the IBDs.
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NTDs are connected to the same-chain CCDs by flexible hinges
(black curves). Association of the two dimers during synaptic
complex assembly involves a swap of an NTD from each dimer to
interact with a CCD from the opposing dimer. When loaded,
LEDGF would engage the CCDs from one dimer and an NTD
from another, effectively stabilizing the complex. Further, it is also
speculatively possible that the other NTD interacts with the IBD,
as seen with the dark blue NTD in (A). (D) Alternative model for
the assembly of the synaptic complex in which there is no NTD
swap. In this case the IBD of LEDGF stabilizes the synaptic
complex by locking the NTDs in the correct orientation for
tetramerization.
Found at: doi:10.1371/journal.ppat.1000259.s004 (0.81 MB JPG)
Figure S4 Validation of LEDGF-Dependent Concerted HIV-1
IN Strand Transfer Activity. (A) Increasing input of donor DNA
favors concerted integration. Lane 1 contains a mock sample,
where IN and LEDGF were omitted; lane 2 shows activity in the
absence of LEDGF; lane 3 contained both LEDGF and IN, but no
donor DNA. Lanes 4–9: HIV-1 IN was incubated with 1 mM-
4 nM (as indicated) blunt 32-bp donor DNA mimicking the U5
HIV-1 cDNA end and supercoiled target DNA in the presence of
LEDGF. (B) HIV-1 IN strand transfer inhibitor MK0518
(Raltegravir) effectively blocks accumulation of full- and half-site
reaction products. Lanes 4–9: HIV-1 IN was incubated with
0.5 mM pre-processed 32-bp donor DNA in the presence of
LEDGF and MK0518 at final concentrations of 1,400 mM (lane
4), 140 mM (lane 5), 14 mM (lane 6), 1.4 mM (lane 7), 0.14 mM
(lane 8), or 0.014 mM (lane 9). Almost complete suppression of
half- and full-site integration is achieved at 1.4 mM MK0518,
which is comparable to the concentration of IN (0.8 mM) used in
this experiment. The inhibitor was not present in lane 3. Lane 1
contained a mock sample without IN and LEDGF; the cofactor
was omitted from the reaction in lane 2. Migration positions of
DNA size standards, DNA substrate, open circular (o.c.), and
supercoiled (s.c.) target DNA forms, half- and concerted (full-site)
products are indicated. (C) 2-D agarose gel analysis of reaction
products formed under conditions of enhanced concerted
integration. DNA species obtained from incubation of pre-
processed 32-bp donor DNA and supercoiled pGEM target in
the presence of HIV-1 IN and LEDGF (lane 1), IN alone (lane 2),
or in the absence of both proteins (lane 3) were separated in 0.6%
agarose along with 1-kb ladder DNA (lane L) (top gel). A lane with
a sample identical to that in lane 1 was excised from the gel. In this
gel slice, two wells were created for parallel separation of the 1-kb
DNA ladder and another aliquot of sample 1. The DNA was then
separated in the perpendicular direction in a 1.6% agarose gel and
visualized with ethidium bromide. Projected migrations of the
linear DNA standards are indicated with red crosses. Note
migration of the full-site (FS) product along the arc defined by
the linear DNA size standards, while circular DNA species (half-
site [HS], o.c. and s.c. target DNA) appear above the arc. Products
of multiple full-site events are expected to result in a gamut of
linear DNA species of variable lengths migrating as smears in
agarose gels; akin to the full-site product, these species distribute
along the arc.
Found at: doi:10.1371/journal.ppat.1000259.s005 (2.33 MB TIF)
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